C/EBPα and PU.1 are the basic transcription factors that control differentiation-related genes, including granulocyte- colony-stimulating factor (G-CSFR) and human neutrophil elastase (HNE). Here, we analyzed a role of C/EBPα and PU.1 in human acute leukemia cell lines, HL-60 and NB4, in association with a modified chromatin structure by histone deacetylase inhibitors, FK228, sodium phenyl butyrate and vitamin B3. We found that sodium phenyl butyrate alone and 6h-pretreatment with phenyl butyrate or FK228 before the induction of differentiation with all-trans-retinoic acid in the presence of vitamin B3 effectively accelerated and enhanced differentiation to granulocytes in HL-60 but not in NB4 cells as detected by NBT test and the expression of CD11b and CD114 (G-CSFR) using flow cytometric analysis. HDACIs induced a time- and dose-dependent accumulation of hyper-acetylated histone H4 in both cell lines with the delay in NB4 cells. Time-dependent different induction of HL-60 and NB4 cell differentiation was paralleled by the activation of C/EBPα and PU.1 binding to the G-CSFR and the HNE promoters in electrophoretic mobility shift assay. Chromatin immunoprecipitation analysis revealed histone H4 acetylation in the G-CSF receptor promoter at the C/EBPα binding site in HL-60 but not in NB4 cells under the combined treatment. The results indicate that epigenetic events, such as histone acetylation, are involved in the activity modulation of the key transcription factors responsible for the induction of granulocytic differentiation in promyelocytic leukemia cells.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.diff.2010.08.003DOI Listing

Publication Analysis

Top Keywords

hl-60 nb4
20
c/ebpα pu1
16
nb4 cells
16
phenyl butyrate
12
promyelocytic leukemia
8
transcription factors
8
cell lines
8
sodium phenyl
8
histone acetylation
8
nb4
6

Similar Publications

A novel therapeutic strategy for leukopenia: Miltefosine activates the Ras/MEK/ERK pathway to promote neutrophil differentiation.

Biochem Biophys Res Commun

February 2025

Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, China. Electronic address:

Leukopenia, marked by diminished white blood cell (WBC) counts, presents significant challenges in the management of hematological malignancies and immunocompromised patients. This study evaluated the therapeutic potential of miltefosine (MFS), a phospholipid analogue, for treating leukopenia. In vitro studies using HL60 and NB4 cells revealed that MFS effectively promoted neutrophil differentiation and function, evidenced by the upregulation of surface markers CD11b, CD11c, CD14, and CD15, as well as enhanced bactericidal activity assessed through the NBT reduction assay.

View Article and Find Full Text PDF

Differentiation therapy with all-trans retinoic acid (ATRA) is well established for acute promyelocytic leukemia (APL). However, the narrow application and tolerance development of ATRA remain to be improved. A number of kinase inhibitors have been reported to induce cell differentiation.

View Article and Find Full Text PDF

MEF2A is a transcription factor for circPVT1 and contributes to the malignancy of acute myeloid leukemia.

Int J Oncol

November 2024

Department of Hematology, Hematology Research Center of Yunnan Province, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China.

Article Synopsis
  • Acute myeloid leukemia (AML) has a high risk of relapse and poor survival, with key roles played by circPVT1 and MEF2A in cancer progression that are still being investigated.
  • Research showed that circPVT1 is overexpressed in AML and is regulated by MEF2A, which enhances cell survival and promotes processes linked to cancer spread called epithelial-mesenchymal transition (EMT).
  • CircPVT1 targets microRNA (miR)-455-3p, influencing the regulation of the MCL1 protein to facilitate cancer cell viability and EMT, suggesting that interrupting this pathway could be a potential therapeutic approach for AML.
View Article and Find Full Text PDF
Article Synopsis
  • Differentiation therapy with all-trans retinoic acid (ATRA) is effective for acute promyelocytic leukemia (APL), but there are limitations in its tolerance and application that prompted researchers to seek new inducers of myeloid differentiation.
  • The study identified the kinase inhibitors PD169316, SB203580, SB202190, and triciribine (TCN) as potent enhancers of CD11b expression in APL cells, with a focus on TCN due to its good tolerance in patients.
  • TCN promotes the differentiation of APL and acute myeloid leukemia (AML) cells by activating the ERK pathway and enhancing pathways associated with hematopoietic lineage and cytokine interactions, revealing
View Article and Find Full Text PDF

Combining new therapeutics with all--retinoic acid (ATRA) could improve the efficiency of acute myeloid leukemia (AML) treatment. Modeling the process of ATRA-induced differentiation based on the transcriptomic profile of leukemic cells resulted in the identification of key targets that can be used to increase the therapeutic effect of ATRA. The genome-scale transcriptome analysis revealed the early molecular response to the ATRA treatment of HL-60 cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!